Background: Rapid detection of changes in cardiac index (CI) in real time using minimally invasive monitors may be of clinical benefit. We tested whether the Starling-SV bioreactance device, which averages CI over a short 8 s period, could assess the effects of passive leg raising (PLR), a clinical test that is recommended to assess fluid responsiveness during septic shock. Methods: In 32 critically ill patients, we measured CI by transpulmonary thermodilution (PiCCO2, CI td ), pulse contour analysis (PiCCO2, CI Pulse ), and the Starling-SV device (CI Starling ) at baseline. CI Pulse and CI Starling were measured again at the end of a PLR test. In the 13 patients with a positive PLR test, CI td , CI Pulse , and CI Starling were measured before and after a 500 ml saline infusion. The primary outcome was relative changes from baseline measurements in CI td , CI Pulse , and CI Starling . Secondary outcomes compared absolute values measured by each method. Results: Relative changes in CI Pulse and CI td were significantly correlated (r¼0.82; n¼45; P<0.001), with an 89% concordance rate (n¼45 paired measurements). Relative changes in CI Starling and CI td were also significantly correlated (r¼0.59; n¼45; P<0.001) with a 78% concordance rate. For absolute measures of CI (n¼77 paired measurements), the bias between CI Pulse and CI td was 0.01 L min À1 m À2 (limits of agreement, e0.49 and 0.51 L min À1 m
Reliable monitoring of cardiac output in the intensive care unit has mostly been achieved by invasive methods. More recently, interest has increased in the utility of minimally invasive techniques, 1 including bioreactance. 2 Bioreactance is based on the measurement of the phase shift of an oscillating low voltage current that occurs when it crosses the thorax. 3, 4 In contrast to other reports, 5 we found a bioreactance device (Nicom; Cheetah Medical, Newton Center, MA, USA) was unable to track changes in cardiac index (CI) in critically ill patients with haemodynamic compromise. 6 In particular, this device was unable to detect changes in CI during a passive leg raising (PLR) test, a postural change used to detect preload dependence 7 and which is now recommended to assess fluid responsiveness during septic shock. 8 However, the PLR test requires a direct and real-time measurement of cardiac output. 9 These conflicting results may, therefore, be related to the long period of sampling time (30 s) over which previous bioreactance devices averaged CI. 10, 11 In the present study, we tested whether a bioreactance (hereafter Starling-SV) device, for which the averaging time of CI had been reduced to 8 s, could accurately assess the effects of a passive leg raise test and predict fluid responsiveness.
Methods

Patients
This prospective study was carried out in a 25-bed medical intensive care unit of a university hospital during a 12 month period. It was approved by our local institutional review board (Comit e pour la protection des personnes Ile-de-France VII). All patients or their relatives gave informed consent.
The inclusion criteria were: age !18 yr, a transpulmonary thermodilution device in place for clinical purposes (PiCCO2; Pulsion Medical Systems, Feldkirchen, Germany) and a decision by the clinicians in charge to perform a PLR test. Patients were excluded if the investigators were not available or if the PLR manoeuvre was not clinically inadvisable (intracranial hypertension, venous compression stocking, intra-abdominal hypertension).
Bioreactance measurements
The Starling bioreactance system requires the application of four double electrode sensors on the skin of the thorax.
12
Upper sensors were placed on the mid-left and mid-right clavicles and lower sensors in the mid-left and mid-right last rib. The outer electrodes in each electrode pair delivers a known alternating high-frequency current that is sensed by the inner electrode pair. Changes in thoracic pulsatile blood volume alter the phase modulation between currents recorded at inner and outer electrodes. A proprietary algorithm computes CI from this change in phase.
In a previous version of the (Nicom) bioreactance device, the value of CI displayed on the screen of the device results from averaging of the values of CI recorded during the past 30 s. For the purpose of the study, we used a device (hereafter Starling-SV) that was modified in order to shorten the time of this moving average to 8 s.
Measurements by transpulmonary thermodilution and pulse contour analysis
The PICCO2 device requires a central venous catheter in the superior vena cava and a thermistor-tipped catheter inserted through the femoral artery. It measures CI through two methods. The first method, transpulmonary thermodilution, requires the injection in the superior vena cava of 15 ml cold saline. CI is estimated from the analysis of the thermodilution curve recorded at the tip of the arterial catheter. 13 Provided that three measurements are averaged, the least significant change of the measurement is between 10% and 15%. 14 The second method used by the PiCCO2 device for measuring CI is pulse contour analysis. 15 It is based on a proprietary algorithm analysing the waveform of the arterial curve obtained through the femoral catheter. 13 It provides a beat-by-beat estimation of CI that is averaged over 12 s. This estimation of CI (CI Pulse ), which may drift over time, is 'recalibrated' when transpulmonary thermodilution is performed. This technique has been demonstrated to be precise. 13 
Study design
At Baseline #1, a set of thermodilution measurements was performed in order to calibrate CI Pulse ( Supplementary Fig. S1 ).
We recorded the values of CI provided by the bioreactance device (CI Starling ), CI td and CI Pulse . We also recorded heart rate and central venous and arterial pressures. A PLR test was then performed. By using the automated bed adjustment, the patient was moved from the semi-recumbent position to a position where the trunk was horizontal and the lower limbs lifted at 45 . 9 When CI Pulse , CI Pulse and CI Starling had reached their maximal value during PLR, they were recorded ( Supplementary Fig. S1 ). No thermodilution measurement was performed at this time, because the effects of PLR must be assessed in real time. 9 Then, the patient was moved back in the semi-recumbent position and CI Pulse was allowed to return to baseline (Baseline #2). A set of transpulmonary thermodilution measurements was performed. We performed the same measurements as at Baseline #1 ( Supplementary Fig. S1 ). At this time, CI Pulse was measured before CI td , such that it was not calibrated by transpulmonary thermodilution ( Supplementary  Fig. S1 ). If CI Pulse increased !10% during PLR compared with the Baseline #1 value, the patient was considered 'preload responsive' 13 and was administered 500 ml of normal saline over 10 min. After volume expansion in these patients, a last set of haemodynamic measurements was obtained, including the same variables as at Baselines #1 and #2 ( Supplementary  Fig. S1 ). In patients with a negative PLR test ('non-preload
Editor's key points
Rapid detection of changes in cardiac index (CI) using minimally invasive monitoring may enhance the assessment of fluid responsiveness in critical illness. This small single-centre study compared a bioreactance monitor, which averages CI over a short 8 s period, with transpulmonary thermodilution and pulse contour analysis to detect haemodynamic changes during passive leg raising. The error in measuring cardiac index was large for bioreactance.
The clinical utility of less invasive bioreactance monitoring to assess fluid responsiveness remains uncertain.
responsive'), no fluid was infused. Catecholamine dosages and ventilation settings were kept constant during the study period.
Data analysis
A study analysis plan was not registered prospectively. The primary outcome of the study was to test the trending ability of the Starling-SV bioreactance device during a PLR test (i.e. to reliably follow the effects of PLR on CI Pulse ). The secondary outcome was to test the accuracy of the Starling-SV device to measure absolute values of CI. For the primary goal, we compared the changes in CI Starling with the changes in CI Pulse during a PLR test. We also tested the ability of changes in CI Starling between Baseline #1 and PLR to detect simultaneous changes in CI Pulse !10% (the threshold of CI changes defining a positive PLR test 13 ). For this purpose, CI Pulse was considered as the reference technique for two reasons. The first is that the effects of PLR must be assessed by a real-time monitoring of CI. 9 The second is that the least significant change in CI td is too
high for a precise measurement of the changes in CI induced by PLR. 14 As only patients with a positive PLR test received fluid, we could not test the ability of the PLR-induced changes in CI Starling to test fluid responsiveness. For the secondary part of the study, CI td was considered as the reference technique.
We compared the absolute values of CI Pulse and CI Starling with the absolute values of CI td at all study times when all three were measured together: Baseline #1, Baseline #2, and after volume expansion.
Statistics
The normality of data distribution was tested with the KolmogoroveSmirnov test. Data are expressed as mean [standard deviation (SD)], median (interquartile range), or number (frequency in %). Comparison of haemodynamic variables between time points of the study was assessed using the paired Student's t-test or the Wilcoxon test, depending on the data distribution. Comparison between PLR responders and PLR non-responders was assessed using the two-sample Student's t-test or the ManneWhitney U-test, depending on the data distribution. The comparison between absolute values of CI Pulse and CI Starling and absolute values of CI td measured at Baseline #1, Baseline #2, and after volume expansion (in cases in which the latter was performed) was performed by using the BlandeAltman analysis. The percentage error was calculated as 2SD divided by the mean of CI td . 15 The changes in CI Pulse and CI Starling produced by PLR test and by volume expansion (if performed) were compared with the simultaneous changes in CI td by polar plot and four quadrant analyses. We analysed the absolute changes in CI (with an exclusion zone of 0.5 L min À1 m À2 ) and the relative changes in CI (with an exclusion zone of 15%). 14 For the polar plot analysis, an acceptable trending ability was defined as a mean polar angle within ±5 and radial limits of agreement within ±30 . The ability of the PLR-induced changes in CI Starling to detect a positive PLR test (defined by an increase in CI Pulse !10%) was assessed using a receiving operating characteristic (ROC) curve. Sensitivity, specificity, and positive and negative predictive values are expressed as median (95% confidence interval). The cut-off value of PLR-induced changes in CI Starling for detecting a positive PLR test defined by an increase CI Pulse !10% was considered as the one providing the lowest Youden index.
Sample size calculation
We calculated that 13 patients in each group were needed to establish a difference between the area under the ROC curve of 0.9 and 0.6. When this number was reached in one group, we continued inclusions in this group until the second one also reached 13 patients. Patients were included depending on the investigators' availability. All statistical analyses were performed with MedCalc software (version 17.6; MedCalc Software, Mariakerke, Belgium). The threshold for statistical significance was set at P<0.05.
Results
Patient characteristics
Fifty-three patients were screened. Twenty-one were not included because the investigators were not available. No patient was excluded for other reasons. Thirteen patients who were preload responsive and 19 preload non-responders were included in the study (Table 1) . No patient was withdrawn from analysis or lost at follow-up. Sepsis was the most common aetiology of shock. The majority of patients were receiving norepinephrine. No other vasoactive drug was infused.
Primary outcome: comparison of relative changes in CI Pulse and CI Starling with CI td Forty-five paired comparisons were made between CI td , CI Pulse , and CI Starling . A total of 32 comparisons were made between Baseline #1 and Baseline #2, and 13 comparisons were made between Baseline #2 and after volume expansion. Relative changes in CI Pulse and CI td were significantly correlated (r¼0.82; n¼45; P<0.001); the concordance rate was 89% (Fig. 1) . Relative changes in CI Starling and CI td were significantly correlated (r¼0.59; n¼45; P<0.001) with a 78% concordance rate (Fig. 1) . ; Supplementary Fig. S2 ) and 15% percentage error between CI td and CI Pulse . Similar results were obtained for the subgroup of patients with atrial fibrillation (n¼6; Supplementary Fig. S3 ).
The bias between CI Starling and CI td was 0.03 L min À1 m
À2
(n¼77 paired measurements), with limits of agreement e1.61 and 1.67 L min À1 m À2 (Fig. 3) and 48% percentage error between CI Starling and CI td . When excluding data from Baseline #1 and considering all measurements of CI td and CI Starling performed at Baseline #2 (n¼32) and after volume expansion (n¼13), the bias between CI Starling and CI td was e0.01 L min À1 m
. The limits of agreement were e1.68 and 1.66 L min À1 m
( Supplementary Fig. S2 ), with 54% percentage error. Comparisons between absolute values of CI measured by pulse contour analysis (CI Pulse ) and by the Starling SV-device (CI Starling ) are shown in Supplementary Fig. S4 .
Polar plot and four quadrant analyses of absolute changes measured between monitors
Similar polar plots were observed across all comparisons. For absolute changes in CI td and CI Pulse , the polar plot had a mean polar angle of e2 with limits of agreement of e28 to 24 ( Supplementary Fig. S5 ). For absolute changes in CI td and CI Starling , the polar plot had a mean polar angle of 10 with limits of agreement of e23 to 44 (Supplementary Fig. S5 ).
Discussion
In a population of critically ill patients, our study shows that a bioreactance device modified to average CI over 8 s was able to assess the effects of a PLR test with an acceptable sensitivity and specificity. Bioreactance derives cardiac output from the analysis of the phase shift of a high-frequency (75 kHz) current across the thorax. 3 At systole, the pulsatile ejection of blood from the heart instantly generates changes in the amplitude and phase of the thoracic electrical impedance. 3 While the traditional bioimpedance technique measured the change in impedance amplitude, the bioreactance technique detects and quantifies the change in its phase. The majority of this phase shift is attributable to a change in the aortic volume. Therefore, the bioreactance signal is correlated almost totally with aortic flow. 3 In practice, this system only requires four dual 'stickers' that are used as electrodes. Few studies have investigated the reliability of bioreactance for measuring cardiac output, with several reporting discordant results. 4,6,16e23 In a study of similar design to the present one, we found that another, previous generation (Nicom) bioreactance device failed to accurately estimate CI compared with transpulmonary thermodilution and pulse contour analysis. 6 This bioreactance device was also inaccurate for tracking the changes in CI and also unable to assess the effects of a PLR test. 6 As the minimum time response of the device used in previous studies is 30 s, 10 this may have impeded the assessment of the PLR-induced short-term changes in CI. 10, 11 In contrast, in the present study, the Starling-SV bioreactance device averaged CI over 8 s.
We found that the percentage error of the modified version of the Starling-SV device when compared with transpulmonary thermodilution was more than 30%, the maximal threshold usually used to define interchangeability. 15 This result is in accordance with our previous study. 6 The discordance between the tracking ability of the Starling-SV device when compared with either CI td or CI Pulse might be explained by the different properties of transpulmonary thermodilution and pulse contour analysis. Transpulmonary thermodilution provides reliable measurements of cardiac output, but with poor precision. 26 This is the reason why it is necessary to average several measurements of CI td to obtain a reliable measurement. The least significant changes in CI td are around 12% when three measurements are averaged. 14 CI td is not appropriate for estimating changes in cardiac output of small amplitude, such as those elicited by PLR. CI Pulse , which has a much better precision, 27 is more appropriate for this purpose. The precision of CI Starling , a continuous method of measurement, may also be sufficient. 4, 25, 28 Therefore, even if measurement of absolute cardiac output is not perfectly accurate, the Starling-SV might be able to track changes in cardiac output when compared with CI Pulse . We acknowledge that the Starling-SV bioreactance device does not provide all of the information provided by more invasive measurements, which also applies to other less invasive devices. 2, 27, 29 In clinical practice, the relative changes in cardiac output are more informative than the absolute values. 14, 15 This is particularly true for assessing fluid responsiveness through dynamic indices, which require beatto-beat and precise measurement. For some of the tests of fluid responsiveness, the diagnostic threshold of cardiac output changes is small, including the end-expiratory occlusion test, 30 mini fluid challenge, 31 and the tidal volume test. 32 A significant limitation of our study is that we did not evaluate the Starling-SV device for assessing these tests, which should be explored in further studies. Another limitation is that we included few patients with atrial fibrillation, although the reliability of the Starling-SV device to detect trends of CO appears acceptable.
For technical reasons, we could not compare directly in the same measurements averaging periods of 8 and 30 s. Therefore, the apparent improvements in CI tracking compared with our previous study 6 may not be solely attributable to the change to an 8 s averaging version. Further studies should investigate to which extent the shortening of the averaging time reduces the precision of measurement of the Starling-SV bioreactance device. In summary, a bioreactance device with a shorter averaging period was able to assess the haemodynamic effects of a PLR test with reasonable accuracy in a population of critically ill patients. Further work is required to establish the clinical utility of less invasive bioreactance monitoring to assess fluid responsiveness. 
